NCT03731442 is a Phase 3 clinical trial of Involved field irradiation in Esophageal Cancer, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT03731442?

NCT03731442 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03731442?

Interventions in NCT03731442: Involved field irradiation, Elective field irradiation, Paclitaxel, Platinum, PEG-rhG-CSF.

What condition does NCT03731442 study?

NCT03731442 studies Esophageal Cancer.

Is NCT03731442 still recruiting?

NCT03731442 is currently recruiting now. Last updated 12 December 2018.

Last reviewed 2018-12-12 · How we verify

NCT03731442

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Recruiting now Phase 3 Last updated 12 December 2018

What this trial tests

Phase 3 trial testing Involved field irradiation in Esophageal Cancer in 300 participants. Currently enrolling.

Timeline

1 November 2018

Primary endpoint
31 October 2022

31 October 2027

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	300
Start date	1 November 2018
Primary completion	31 October 2022
Estimated completion	31 October 2027
Sites	1 location across China

Drugs / interventions tested

Involved field irradiation
Elective field irradiation
Paclitaxel — full drug profile →
Platinum (PLATINUM) — full drug profile →
PEG-rhG-CSF — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 16 to 70, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol.
Chang X, Deng L, Ni W, Li C, et al · · 2020 · cited 1× · PMID 32928136 · DOI 10.1186/s12885-020-07315-0
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients: A Prospective, Multicenter Clinical Trial Protocol
Chang X, Deng L, Ni W, Li C, et al · · 2020 · DOI 10.21203/rs.3.rs-35239/v1

Verify or expand the search:

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03731442 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 12 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03731442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing